Product Name :
JNJ-38877618
Description:
JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.
CAS:
943540-74-7
Molecular Weight:
374.35
Formula:
C20H12F2N6
Chemical Name:
6-difluoro[6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methylquinoline
Smiles :
FC(F)(C1=NN=C2C=CC(=NN21)C1C=CN=CC=1)C1C=C2C=CC=NC2=CC=1
InChiKey:
KOAWAWHSMVKCON-UHFFFAOYSA-N
InChi :
InChI=1S/C20H12F2N6/c21-20(22,15-3-4-16-14(12-15)2-1-9-24-16)19-26-25-18-6-5-17(27-28(18)19)13-7-10-23-11-8-13/h1-12H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.|Product information|CAS Number: 943540-74-7|Molecular Weight: 374.35|Formula: C20H12F2N6|Chemical Name: 6-difluoro[6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methylquinoline|Smiles: FC(F)(C1=NN=C2C=CC(=NN21)C1C=CN=CC=1)C1C=C2C=CC=NC2=CC=1|InChiKey: KOAWAWHSMVKCON-UHFFFAOYSA-N|InChi: InChI=1S/C20H12F2N6/c21-20(22,15-3-4-16-14(12-15)2-1-9-24-16)19-26-25-18-6-5-17(27-28(18)19)13-7-10-23-11-8-13/h1-12H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 5 mg/mL (13.36 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.Ritlecitinib manufacturer |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|OMO-1 (formerly JNJ-38877618), is a potent, highly selective, orally bioavailable Met kinase inhibitor with nM binding affinity (Kd=1.Bongkrekic acid manufacturer 4 nM) and enzyme inhibitory activity against wt and M1268T mutant Met (2 and 3 nM IC50).PMID:31973585 Met inhibitory effects are assessed in proliferation, colony formation and motility assays. JNJ-38877618 displays nM potency against Met Ampl/mutant and therapy resistant models.|In Vivo:|JNJ-38877618 induces complete inhibition of tumor growth in 3 models: the SNU5 Met amp gastric, U87-MG HGF autocrine glioblastoma and Hs746T Met exon 14 skipping mutant gastric cancer. JNJ-38877618 induces regression of large Met amplified EBC-1 SqNSCLC where JNJ-38877618 leads to dose- and time-dependent inhibition of Met kinase activation, with the duration of target shut down considerably exceeding plasma exposure times. Combination treatments are well tolerated and improved EGFR targeted therapy.|Products are for research use only. Not for human use.|